Irina Bancos
A5034012396- Adrenal and Paraganglionic Tumors
- Hormonal Regulation and Hypertension
- Pituitary Gland Disorders and Treatments
- Adrenal Hormones and Disorders
- Cancer, Hypoxia, and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Sexual Differentiation and Disorders
- Hormonal and reproductive studies
- Stress Responses and Cortisol
- Neuroendocrine Tumor Research Advances
- Cardiac tumors and thrombi
- Meningioma and schwannoma management
- Vitamin D Research Studies
- Mitochondrial Function and Pathology
- High Altitude and Hypoxia
- Cardiac, Anesthesia and Surgical Outcomes
- Thyroid Disorders and Treatments
- Ovarian function and disorders
- Neurofibromatosis and Schwannoma Cases
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Diet and metabolism studies
- Ovarian cancer diagnosis and treatment
- Blood Pressure and Hypertension Studies
Mayo Clinic
2016-2025
WinnMed
2016-2025
University of Minnesota Rochester
2013-2025
Mayo Clinic in Arizona
2016-2025
Mayo Clinic in Florida
2012-2025
Children's Hospital of Pittsburgh
2024
Ludwig-Maximilians-Universität München
2024
University College London
2024
The University of Texas Southwestern Medical Center
2024
Arab American Pharmacist Association
2023
: By definition, an adrenal incidentaloma is asymptomatic mass detected on imaging not performed for suspected disease. In most cases, incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent conditions requiring therapeutic intervention (e.g. carcinoma, pheochromocytoma, hormone-producing adenoma or metastasis). The purpose of this guideline to provide clinicians with best possible evidence-based recommendations clinical management patients based the GRADE (Grading...
Adrenal incidentalomas are adrenal masses detected on imaging performed for reasons other than suspected disease. In most cases, nonfunctioning adrenocortical adenomas but may also require therapeutic intervention including that carcinoma, pheochromocytoma, hormone-producing adenoma, or metastases. Here, we provide a revision of the first international, interdisciplinary guidelines incidentalomas. We followed Grading Recommendations Assessment, Development and Evaluation system updated...
Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare knowledge of the natural history is limited.We aimed to describe baseline characteristics outcomes patients with malignant PHEO PGL (PPGL) identify predictors shorter survival.Retrospective review PPGL evaluated from 1960 2016.Referral center.The group comprised 272 patients.Baseline description, survival outcomes, were in rapidly progressive (n = 29) indolent disease 188).Malignant was diagnosed at a median age 39 years...
Adrenal aldosterone excess is the most common cause of secondary hypertension and associated with increased cardiovascular morbidity. However, adverse metabolic risk in primary aldosteronism extends beyond hypertension, rates insulin resistance, type 2 diabetes, osteoporosis, which cannot be easily explained by excess.We performed mass spectrometry-based analysis a 24-hour urine steroid metabolome 174 newly diagnosed patients (103 unilateral adenomas, 71 bilateral adrenal hyperplasias)...
Cross-sectional imaging regularly results in incidental discovery of adrenal tumours, requiring exclusion adrenocortical carcinoma (ACC). However, differentiation is hampered by poor specificity characteristics. We aimed to validate a urine steroid metabolomics approach, using profiling as the diagnostic basis for ACC.
Adrenalectomy is the definitive treatment for multiple adrenal abnormalities. Advances in technology and genomics an improved understanding of pathophysiology have altered operative techniques indications.To develop evidence-based recommendations to enhance appropriate, safe, effective approaches adrenalectomy.A multidisciplinary panel identified investigated 7 categories relevant clinical concern practicing surgeons. Questions were structured framework Population, Intervention/Exposure,...
Background: Benign adrenal tumors are commonly discovered on cross-sectional imaging. Mild autonomous cortisol secretion (MACS) is regularly diagnosed, but its effect cardiometabolic disease in affected persons ill defined. Objective: To determine burden and steroid excretion with benign without MACS. Design: Cross-sectional study. Setting: 14 endocrine secondary tertiary care centers (recruitment from 2011 to 2016). Participants: 1305 prospectively recruited tumors. Measurements: Cortisol...
Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic dosing, which predisposes to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels phase 2 trials involving CAH.
Abstract Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy, being risk for glucocorticoid-induced adrenal insufficiency. is dependent on dose, duration potency glucocorticoid, route administration, individual susceptibility. Once insufficiency develops or suspected, it necessitates careful education management affected patients. Tapering glucocorticoids can be challenging...
Modern pheochromocytomas (PHEOs) are often discovered by incidental finding on cross-sectional imaging or mutation-based genetic case detection testing. Little is known about how these PHEOs behave.To describe the characteristics and behavior of incidentally through testing.Retrospective study.Referral center.Consecutive patients with pathology-confirmed PHEOs, treated from 2005 to 2016.Tumor size, plasma/urine fractionated metanephrines catecholamines, preoperative management.Two hundred...
Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In the evaluation AI, it is generally recommended that PCC be excluded by measurement plasma-free or 24-hour urinary fractionated metanephrines. However, recent studies suggest biochemical exclusion not performed for lesions with CT characteristics an adrenocortical adenoma (ACA).